Form 4: Processa Pharmaceuticals Executive David Young Reports Changes in Beneficial Ownership

David Young, President of Research & Development at Processa Pharmaceuticals, reports transactions involving common stock and restricted stock units.

Summary

• On April 5, 2024, David Young acquired 1,675 shares of common stock and disposed of 518 shares at $2.79.
• On July 10, 2024, he acquired 644 shares of common stock and disposed of 282 shares at $1.71.
• Following these transactions, Young directly owns 80,905 shares of common stock.
• He also indirectly owns 30,985 shares through the Young-Plaisance Revocable Trust, 10,786 shares through family entities, and 18,544 shares through CorLyst, LLC.
• Young also holds restricted stock units representing a contingent right to receive common stock, with varying vesting schedules and performance goals, totaling 25,155 units.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing. It simply reports transactions and doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The information disclosed is consistent with regulatory requirements for reporting changes in beneficial ownership.
• Similar filings are made by executives at comparable pharmaceutical companies like Amgen, Pfizer, and Johnson & Johnson.

Stakeholder Impact

• Shareholders can use this information to understand the trading activity of a key executive.
• The transactions may have a minor impact on the stock price, depending on market perception.

Key Dates

Keywords

beneficial ownership, Processa Pharmaceuticals, David Young, common stock, restricted stock units, Form 4, insider trading